Beam Therapeutics Inc. (BEAM): Price and Financial Metrics
GET POWR RATINGS... FREE!
BEAM POWR Grades
- Value is the dimension where BEAM ranks best; there it ranks ahead of 37.07% of US stocks.
- BEAM's strongest trending metric is Growth; it's been moving down over the last 179 days.
- BEAM's current lowest rank is in the Stability metric (where it is better than 1.88% of US stocks).
BEAM Stock Summary
- Of note is the ratio of BEAM THERAPEUTICS INC's sales and general administrative expense to its total operating expenses; only 8.36% of US stocks have a lower such ratio.
- BEAM's price/sales ratio is 43.58; that's higher than the P/S ratio of 96.14% of US stocks.
- Revenue growth over the past 12 months for BEAM THERAPEUTICS INC comes in at 320,383.3%, a number that bests 100% of the US stocks we're tracking.
- Stocks that are quantitatively similar to BEAM, based on their financial statements, market capitalization, and price volatility, are LYRA, NCTY, ZOM, MDGS, and LPCN.
- BEAM's SEC filings can be seen here. And to visit BEAM THERAPEUTICS INC's official web site, go to www.beamtx.com.
BEAM Valuation Summary
- BEAM's EV/EBIT ratio is -13.7; this is 271.25% lower than that of the median Healthcare stock.
- BEAM's price/earnings ratio has moved down 7 over the prior 32 months.
Below are key valuation metrics over time for BEAM.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| BEAM | 2022-09-23 | 43.1 | 4.1 | -14.2 | -13.7 |
| BEAM | 2022-09-22 | 44.0 | 4.2 | -14.5 | -14.0 |
| BEAM | 2022-09-21 | 47.2 | 4.5 | -15.5 | -15.1 |
| BEAM | 2022-09-20 | 48.9 | 4.7 | -16.1 | -15.6 |
| BEAM | 2022-09-19 | 49.2 | 4.7 | -16.2 | -15.7 |
| BEAM | 2022-09-16 | 51.3 | 4.9 | -16.9 | -16.4 |
BEAM's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- BEAM has a Quality Grade of D, ranking ahead of 6.52% of graded US stocks.
- BEAM's asset turnover comes in at 0 -- ranking 441st of 682 Pharmaceutical Products stocks.
- 500 - Internal server error
The table below shows BEAM's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0 | 1 | -0.966 |
| 2021-03-31 | 0 | 1 | -1.254 |
| 2020-12-31 | 0 | 1 | -1.054 |
| 2020-09-30 | 0 | 1 | -0.896 |
| 2019-12-31 | 0 | 1 | -1.360 |
BEAM Price Target
For more insight on analysts targets of BEAM, see our BEAM price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $123.57 | Average Broker Recommendation | 1.36 (Strong Buy) |
BEAM Stock Price Chart Interactive Chart >
BEAM Price/Volume Stats
| Current price | $50.95 | 52-week high | $100.06 |
| Prev. close | $51.60 | 52-week low | $27.77 |
| Day low | $48.54 | Volume | 640,000 |
| Day high | $51.28 | Avg. volume | 1,192,347 |
| 50-day MA | $56.86 | Dividend yield | N/A |
| 200-day MA | $55.37 | Market Cap | 3.58B |
Beam Therapeutics Inc. (BEAM) Company Bio
Beam Therapeutics Inc., a biotechnology company, engages in developing precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing therapies for the development of sickle cell disease and beta-thalassemia; CAR-T cell therapies for pediatric T-cell acute lymphoblastic leukemia and pediatric acute myeloid leukemia; therapies for alpha-1 antitrypsin deficiency and glycogen storage disorder 1A; and therapies for ocular and central nervous system disorders. It has a research and clinical collaboration agreement with Magenta Therapeutics, Inc. Beam Therapeutics Inc. was founded in 2017 and is based in Cambridge, Massachusetts.
Latest BEAM News From Around the Web
Below are the latest news stories about BEAM THERAPEUTICS INC that investors may wish to consider to help them evaluate BEAM as an investment opportunity.
ARKG: Too Hard To Pin Down, Too Volatile For ComfortARK Genomic Revolution ETF (BATS:ARKG) is a wildcard of an ETF with an eclectic mix of holdings that reflect the shop’s investment approach in the same way as the other ARK funds. While its large-cap firms and breakout names provide some anchorage, the fund has high exposure to smaller biotech companies, which are arguably the most unlikely and volatile names around which to build a fund’s core. It is our opinion that a portfolio of this type, while it may produce a handful of superstars, is unlikely to provide sufficient return for the massive risk that names in this space bring to the tabl... |
Beam Therapeutics Touts Encouraging Preclinical Data From Gene Editing Approach For Hepatitis B InfectionBeam Therapeutics Inc (NASDAQ: BEAM) announced new preclinical data demonstrating the potential of its multiplex base editing approach to reduce hepatitis B surface antigen (HBsAg) expression and prevent viral rebound of hepatitis B virus (HBV) in vivo models. Base editors are designed to enable direct and irreversible conversion of a specific DNA base into another without inducing double-stranded breaks. In HBV-infected cells, cytosine base editors (CBEs) can target both integrated HBV DNA and |
Beam Therapeutics Presents First In Vivo Data Demonstrating Potential of Multiplex Base Editing Approach to Target Disease Drivers of Chronic Hepatitis B InfectionCAMBRIDGE, Mass., Sept. 19, 2022 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced new preclinical data demonstrating the potential of the company’s multiplex base editing approach to both reduce viral markers – including hepatitis B surface antigen (HBsAg) expression – and prevent viral rebound of hepatitis B virus (HBV) in in vivo models. The data will be presented today, September 19, |
Beam Therapeutics to Participate at the Wells Fargo 2022 Healthcare ConferenceCAMBRIDGE, Mass., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that John Evans, chief executive officer, will present at the Wells Fargo 2022 Healthcare Conference on Thursday, September 8, 2022 at 9:45 a.m. ET in Boston. A live webcast will be available in the investor section of the company's website at www.beamtx.com, and will be archived for 60 days following the |
Why Beam Therapeutics Stock Rocketed Higher This WeekShares of the clinical-stage base-editing company Beam Therapeutics (NASDAQ: BEAM) stormed higher through the first four days of trading this week. Beam's sizable uptick seems to simply be a rebound following last week's 23% drop in its share price. Clinical-stage biotech stocks have been extremely volatile this year, thanks to rising interest rates, geopolitical turmoil, and investors' general aversion to risk right now. |
BEAM Price Returns
| 1-mo | -3.74% |
| 3-mo | -2.04% |
| 6-mo | -1.58% |
| 1-year | -39.27% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -36.06% |
| 2021 | -2.39% |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
Loading social stream, please wait...